Elevations in serum creatinine with RAAS blockade: Why isn't it a sign of kidney injury?

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 5, 2008, Pages 443-449

  Ryan, Michael J ^a   Tuttle, Katherine R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SACRED HEART MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury and dual RAAS blockade; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Renin angiotensin system

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; RAMIPRIL; ANGIOTENSIN RECEPTOR;

ALBUMINURIA; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN SENSITIVITY; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; STENT; BLOOD; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; KIDNEY DISEASE; PHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CREATININE; HUMANS; KIDNEY; KIDNEY DISEASES; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 58149347640     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32830a9606     Document Type: Review

References (96)

1. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17:1695-1702.
2. GoAS,Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
3. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198-206.
4. Vlagopoulos PT, Sarnak MJ. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005; 89:587-611.
5. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41 (5 Suppl):11-17.
6. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116:85-97.
7. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflam-mation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008; 19:593-599.
8. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22:2011 -2022.
9. Segura J, Ruilope LM. Obesity essential hypertension and renin-angiotensin system. Public Health Nutr 2007; 10:1151 -1155.
10. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26:59-62.
11. Coresh J, Stevens LA, Levey AS. Chronic kidney disease is common: what do we do next? Nephrol Dial Transplant 2008; 23:1122-1125.
12. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18:2644-2648.
13. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4:39-45.
14. Durvasula RV, Shankland SJ. The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy. Curr Hypertens Rep 2006; 8:132-138.
15. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69:2131 -2147.
16. Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007; 9:403-408.
17. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008; 7:399-410.
18. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag 2007; 3:937-945.
19. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7:3-14.
20. Victor RG. Pathophysiology of target-organ disease: does angiotensin II remain the key? J Clin Hypertens (Greenwich) 2007; 9 (11 Suppl 4):4-10.
21. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103:919-925.
22. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and metaanalysis. Am J Ther 2008; 15:36-43.
23. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369:1208-1219.
24. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 2008; 3 (Suppl 1):S3-S10.
25. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007; 27:287-293.
26. Abbott KC, Bakris GL. What have we learned from the current trials? Med Clin North Am 2004; 88:189-207.
27. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl 1):S1 -S290.
28. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49:12-26.
29. Jones-Burton C, Mishra SI, Fink JC, et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006; 26:268-275.
30. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: one or many therapies? Kidney Int 2001; 59:1211 -1226.
31. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:288-296.
32. Cravedi P, Ruggenenti P, Remuzzi G. Intensified inhibition of renin-angio-tensin system: a way to improve renal protection? Curr Hypertens Rep 2007; 9:430-436.
33. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of mono-therapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30-48.
34. Sarafidis PA. Proteinuria: natural course, prognostic implications and ther-apeutic considerations. Minerva Med 2007; 98:693-711.
35. Alicic R, Tuttle KR. Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy? Curr Hypertens Rep 2007; 9:393-402.
36. Smith SCJr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38:1581 -1583.
37. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
38. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
39. Duru OK, Li S, Jurkovitz C, et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2008; 51:192-198.
40. Turley A, Roberts AP, Morley R, et al. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up. Interact Cardiovasc Thorac Surg 2008; 7:231 -234.
41. Rasmussen S, Abildstrom SZ, Rasmussen JN, et al. Hospital variation in use of secondary preventive medicine after discharge for first acute myocardial infarction during 1995-2004. Med Care 2008; 46:70-77.
42. Tiwari A, Tseng CL, Kern EF, et al. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease. Am J Manag Care 2007; 13:73-79.
43. Setoguchi S, Levin R, Winkelmayer WC. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. Int J Cardiol 2008; 125:172-177.
44. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153:1064-1073.
45. Mandal AK, Markert RJ, Saklayen MG, et al. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 1994; 42:170-174.
46. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999; 138 (5 Pt 1):849-855.
47. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002; 32 (3 Suppl 1):33-42.
48. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45:531 -539.
49. Dello Strologo L, Massella L, Rizzoni G. Cyclosporine-induced transient renal hypoperfusion in adolescent transplant recipients. Pediatr Nephrol 1996; 10:81 -83.
50. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104:1985-1991.
51. Cupples WA, Braam B. Assessment of renal autoregulation. Am J Physiol Renal Physiol 2007; 292:F1105-F1123.
52. Loutzenhiser R, Griffin K, Williamson G, Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 290:R1153-R1167.
53. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 2007; 18:208-214.
54. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angio-tensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59:251 -287.
55. Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16:1135-1140.
56. Lansang MC, Stevanovic R, Price DA, et al. ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus. Kidney Int 2005; 67:1033-1037.
57. Hollenberg NK. Diabetes, nephropathy, and the renin system. J Hypertens Suppl 2006; 24:S81 -S87.
58. Chan LY, Leung JC, Tang SC, et al. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 2005; 16:2306-2317.
59. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004; 286:F8-F15.
60. Patzak A, Persson AE. Angiotensin II-nitric oxide interaction in the kidney. Curr Opin Nephrol Hypertens 2007; 16:46-51.
61. Arima S, Ito S. The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy. Nephrol Dial Transplant 2003; 18:1966-1969.
62. Sochett EB, Cherney DZ, Curtis JR, et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 2006; 17:1703-1709.
63. Hollenberg NK. Renal implications of angiotensin receptor blockers. Am J Hypertens 2001; 14 (7 Pt 2):237S-241S.
64. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96:793-800.
65. Christensen PK, Akram K, Konig KB, Parving HH. Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. Diabetes Care 2003; 26:156-162.
66. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685-693.
67. Hansen HP, Rossing P, Tarnow L, et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995; 47:1726-1731.
68. Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115:513-519.
69. Van Praet JT, De Vriese AS. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 2007; 16:336-347.
70. Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci 2007; 334:283-290.
71. Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51:521 -526.
72. Toprak O, Cirit M, Bayata S, et al. The effect of preprocedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 2003; 3:98-103.
73. Cirit M, Toprak O, Yesil M, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006; 104:c20-c27.
74. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95:13-19.
75. Ruggenenti P, PernaA, Remuzzi G,Gruppo Italianodi Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12:2832-2837.
76. Klahr S. Primary and secondary results of the modification of diet in renal disease study. Miner Electrolyte Metab 1996; 22:138-142.
77. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354:131-140.
78. Hebert LA. Optimizing ACE-inhibitor therapy for chronic kidney disease. N Engl J Med 2006; 354:189-191.
79. Hollenberg NK. Medical therapy for renovascular hypertension: a review. Am J Hypertens 1988; 1 (4 Pt 2):338S-343S.
80. Losito A, Errico R, Santirosi P, et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 2005; 20:1604-1609.
81. Textor SC. Renovascular hypertension in 2007: where are we now? Curr Cardiol Rep 2007; 9:453-461.
82. Garovic V, Textor SC. Renovascular hypertension: current concepts. Semin Nephrol 2005; 25:261 -271.
83. Brammah A, Robertson S, Tait G, Isles C. Bilateral renovascular disease causing cardiorenal failure. BMJ 2003; 326:489-491.
84. Devoy MA, Tomson CR, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992; 232:493-498.
85. Bax L, Mali WP, Buskens E, et al. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. J Nephrol 2003; 16:807-812.
86. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J 2006; 152:59-66.
87. Mistry S, Ives N, Harding J, et al. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. J Hum Hypertens 2007; 21:511 -515.
88. Zalunardo N, Tuttle KR. Atherosclerotic renal artery stenosis: current status and future directions. Curr Opin Nephrol Hypertens 2004; 13:613-621.
89. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8:529-535.
90. Toto R, Palmer BF. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol 2007; 28:372-380.
91. Weir MR. Effects of renin-angiotensin system inhibition on end-organ pro- tection: can we do better? Clin Ther 2007; 29:1803-1824.
92. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72:879-885.
93. Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24:486-493.
94. MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48:8-20.
95. Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167:1930-1936.
96. Linas SL Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease. Clin J Am Soc Nephrol 2008; 3 (Suppl 1): S17-S23.